Idiopathic Generalized Epilepsy

Neurology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
1 program
PerampanelN/A1 trial
Active Trials
NCT04252846Completed191Est. Jan 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EisaiPerampanel

Clinical Trials (1)

Total enrollment: 191 patients across 1 trials

NCT04252846EisaiPerampanel

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Start: Jul 2020Est. completion: Jan 2023191 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
13h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
13h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
13h ago

Director of Finance

CoMind
London, UK
13h ago

Electronics Engineering Manager

CoMind
London, UK
13h ago

Director of Information Technology

Zavation Medical Products
13h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Epilepsy(296)Multiple Sclerosis(283)Schizophrenia(268)Parkinson Disease(185)Alzheimer's Disease(179)Parkinson's Disease(163)Alzheimer Disease(119)Stroke(102)Depression(84)Relapsing-Remitting Multiple Sclerosis(84)